专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明授权

US06613879B1 FAP-activated anti-tumour compounds 有权
标题翻译： FAP激活的抗肿瘤化合物
公开(公告)号：US06613879B1
公开(公告)日：2003-09-02
申请号：US09553800
申请日：2000-04-21
申请人： Raymond A. Firestone , Wolfgang J. Rettig , Martin Lenter , Stefan Peters , Pilar Garin-Chesa , Juergen Mack , Dietmar Leipert , John E. Park , Leila A. Telan
发明人： Raymond A. Firestone , Wolfgang J. Rettig , Martin Lenter , Stefan Peters , Pilar Garin-Chesa , Juergen Mack , Dietmar Leipert , John E. Park , Leila A. Telan
IPC分类号： C07K508
CPC分类号： B82Y5/00 , A61K38/00 , A61K47/65 , A61K47/67 , C07H15/252 , C07K5/06026 , C07K5/1019 , C07K5/1024
摘要： The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAP&agr;), said prodrug having a cleavage site which is recognised by FAP&agr;, and said drug being cytotoxic or cytostatic under physiological conditions.
摘要翻译：本发明涉及能够通过人成纤维细胞活化蛋白（FAPalpha）的催化作用转化为药物的前体药物，所述前药具有被FAPalpha识别的切割位点，并且所述药物在生理条件下是细胞毒性或细胞生长抑制。

12. 发明授权

US06310185B1 Recombinant human anti-Lewis Y antibodies 失效
标题翻译：重组人抗Lewis Y抗体
公开(公告)号：US06310185B1
公开(公告)日：2001-10-30
申请号：US08207861
申请日：1994-03-08
申请人： Thomas P. Wallace , Kathryn Lesley Armour , Francis Joseph Carr , Lloyd J. Old , Elisabeth Stockert , Sydney Welt , Kunio Kitamura , Pilar Garin-Chesa
发明人： Thomas P. Wallace , Kathryn Lesley Armour , Francis Joseph Carr , Lloyd J. Old , Elisabeth Stockert , Sydney Welt , Kunio Kitamura , Pilar Garin-Chesa
IPC分类号： C07K1630
CPC分类号： C07K16/34 , C07K16/30 , C07K2317/24 , C07K2319/00
摘要： The invention provides for the production of several humanized murine antibodies specific for the antigen Lewis Y, which is recognized by murine atibodies specific for the Lewis Y antigen. The Lewis Y antigen is expressed in normal tissues but the level of expression is higher in certain tumour types so that the antigen can be used as a marker for cells of some breast, colon, gastric, esophageal, pancreatic, duodenal, lung, bladder and renal carcinomas and gastric and islet cell neuroendocrine tumours. The invention also provides for numerous polynucleotide encoding humanized Lewis Y specific antibodies, expression vectors for producing humanized Lewis Y specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized Lewis Y specific antibodies. Additionally, the invention provides methods of treating cancer using humanized Lewis Y specific antibodies.
摘要翻译：本发明提供了对抗原Lewis Y特异性的几种人源化鼠抗体的产生，其被Lewis Y抗原特异性的鼠抗体识别。 Lewis Y抗原在正常组织中表达，但在某些肿瘤类型中表达水平较高，因此抗原可用作乳腺癌，结肠癌，胃癌，食管癌，胰腺癌，十二指肠癌，肺癌，膀胱癌，肾癌和胃和胰岛细胞神经内分泌肿瘤。本发明还提供编码人源化Lewis Y特异性抗体的许多多核苷酸，用于产生人源化Lewis Y特异性抗体的表达载体和用于重组产生人源化抗体的宿主细胞。本发明还提供使用人源化Lewis Y特异性抗体检测癌细胞（体外和体内）的方法。另外，本发明提供使用人源化Lewis Y特异性抗体治疗癌症的方法。

13. 发明授权

US5843448A Tumor rejection antigen precursor 失效
标题翻译：肿瘤排斥抗原前体
公开(公告)号：US5843448A
公开(公告)日：1998-12-01
申请号：US560024
申请日：1995-11-17
申请人： Yao-Tseng Chen , Elisabeth Stockert , Yachi Chen , Pilar Garin-Chesa , Wolfgang J. Rettig , Lloyd J. Old
发明人： Yao-Tseng Chen , Elisabeth Stockert , Yachi Chen , Pilar Garin-Chesa , Wolfgang J. Rettig , Lloyd J. Old
IPC分类号： C12N15/02 , A61K38/00 , A61K39/00 , A61K39/395 , A61P35/00 , C07H21/04 , C07K20060101 , C07K7/08 , C07K14/47 , C07K14/705 , C07K16/30 , C12N5/10 , C12N5/20 , C12P21/08 , C12R1/91 , G01N33/574 , A61K38/10 , C07K14/82
CPC分类号： C07K14/4748 , C07K16/30 , A61K38/00 , A61K39/00
摘要： The invention relates to monoclonal antibodies which specifically bind to the tumor rejection antigen precursor molecule MAGE-1, hybridomas which produce these monoclonal antibodies, and their use. Also described is a recombinant form of MAGE-1, peptides which are useful as immunogens, and immunogenic compositions containing the peptides and an adjuvant.
摘要翻译：本发明涉及与肿瘤排斥抗原前体分子MAGE-1特异性结合的单克隆抗体，产生这些单克隆抗体的杂交瘤及其应用。还描述了重组形式的MAGE-1，可用作免疫原的肽和含有肽和佐剂的免疫原性组合物。

14. 发明授权

US5646253A Recombinant human anti-LK26 antibodies 失效
标题翻译：重组人抗LK26抗体
公开(公告)号：US5646253A
公开(公告)日：1997-07-08
申请号：US207996
申请日：1994-03-08
申请人： Thomas Paul Wallace , William Joseph Harris , Francis Joseph Carr , Wolfgang J. Rettig , Pilar Garin-Chesa , Lloyd J. Old
发明人： Thomas Paul Wallace , William Joseph Harris , Francis Joseph Carr , Wolfgang J. Rettig , Pilar Garin-Chesa , Lloyd J. Old
IPC分类号： G01N33/574 , G01N33/68 , C07K16/46
CPC分类号： G01N33/6854 , G01N33/57484 , G01N33/6833
摘要： The invention provides for the production of several humanized murine antibodies specific for the antigen LK26, which is recognized by the murine antibody LK26. This antigen is expressed on all choriocarcinoma, teratocarcinoma and renal cancer cell lines whereas it is not expressed on cell lines of leukaemias, lymphomas, neuroectodermally-derived and epithelial tumour cell lines (excepting a small subset of epithelial cell lines). Furthermore, whereas renal cancer cell lines express the LK26 antigen, normal renal epithelial cells do not. Similarly, with the exception of the trophoblast, all normal adult and fetal tissues tested are negative for the LK26 phenotype. The invention also provides for numerous polynucleotide encoding humanized LK26 specific antibodies, expression vectors for producing humanized LK26 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized LK26 specific antibodies. Additionally, the invention provides methods of treating cancer using LK26 specific antibodies.
摘要翻译：本发明提供了针对抗原LK26特异的几种人源化鼠抗体的产生，其被鼠抗体LK26识别。该抗原在所有绒毛膜癌，畸胎癌和肾癌细胞系中表达，而不在白血病，淋巴瘤，神经外胚层衍生的和上皮性肿瘤细胞系的细胞系（除了上皮细胞系的一小部分之外）上表达。此外，肾癌细胞株表达LK26抗原时，肾上皮细胞不正常。类似地，除了滋养层之外，所有正常的成年和胎儿组织检测对于LK26表型是阴性的。本发明还提供编码人源化LK26特异性抗体的许多多核苷酸，用于产生人源化LK26特异性抗体的表达载体和用于重组产生人源化抗体的宿主细胞。本发明还提供了使用人源化LK26特异性抗体检测癌细胞（体外和体内）的方法。另外，本发明提供使用LK26特异性抗体治疗癌症的方法。

15. 发明授权

US5565356A Hybridoma cell lines which produce monoclonal antibodies having the properties of monoclonal antibody 100-310 and the monoclonal antibodies produced by these hybridoma cell lines 失效
标题翻译：产生具有单克隆抗体100-310的特性的单克隆抗体的杂交瘤细胞系和由这些杂交瘤细胞系产生的单克隆抗体
公开(公告)号：US5565356A
公开(公告)日：1996-10-15
申请号：US273277
申请日：1994-07-11
申请人： Sydney Welt , Clarence Williams, Jr. , Elsje C. Barendswaard , Chaitanya R. Divgi , Pilar Garin-Chesa , Lloyd J. Old
发明人： Sydney Welt , Clarence Williams, Jr. , Elsje C. Barendswaard , Chaitanya R. Divgi , Pilar Garin-Chesa , Lloyd J. Old
IPC分类号： A61K51/10 , C07K16/30 , C12N5/20
CPC分类号： C07K16/3046 , A61K51/1063
摘要： Monoclonal antibody 100-310 is found to be reactive against colon cancer cells and would therefore be useful for diagnostic imaging and treatment of colon cancer.
摘要翻译：发现单克隆抗体100-310对结肠癌细胞具有反应性，因此可用于结肠癌的诊断成像和治疗。

16. 发明申请

US20140066456A1 COMBINATION THERAPY IN TREATMENT OF CANCER AND FIBROTIC DISEASES 审中-公开
标题翻译：治疗癌症和纤维性疾病的联合治疗
公开(公告)号：US20140066456A1
公开(公告)日：2014-03-06
申请号：US14073030
申请日：2013-11-06
申请人： Joanne VAN RYN , Pilar GARIN-CHESA , Flavio SOLCA
发明人： Joanne VAN RYN , Pilar GARIN-CHESA , Flavio SOLCA
IPC分类号： A61K31/517 , A61K31/496 , A61K31/4439
CPC分类号： A61K31/517 , A61K31/4439 , A61K31/496 , A61K2300/00
摘要： The invention relates to new methods for the treatment of oncological and fibrotic diseases comprising the combined administration of a receptor tyrosine kinase inhibitor in conjunction with a thrombin inhibitor.
摘要翻译：本发明涉及治疗肿瘤和纤维化疾病的新方法，其包括与凝血酶抑制剂联合施用受体酪氨酸激酶抑制剂。

17. 发明授权

US06518415B1 Recombinant human anti-Lewis Y antibodies 失效
标题翻译：重组人抗Lewis Y抗体
公开(公告)号：US06518415B1
公开(公告)日：2003-02-11
申请号：US08859648
申请日：1997-05-20
申请人： Kathryn Lesley Armour , Francis Joseph Carr , Lloyd J. Old , Elisabeth Stockert , Sydney Welt , Kunio Kitamura , Pilar Garin-Chesa
发明人： Kathryn Lesley Armour , Francis Joseph Carr , Lloyd J. Old , Elisabeth Stockert , Sydney Welt , Kunio Kitamura , Pilar Garin-Chesa
IPC分类号： C07H2104
CPC分类号： C07K16/34 , C07K16/30 , C07K2317/24 , C07K2319/00
摘要： The invention provides for the production of several humanized murine antibodies specific for the antigen Lewis Y, which is recognized by the murine antibody Lewis Y. The Lewis Y antigen is expressed in normal tissues but the level of expression is higher in certain tumor types so that the antigen can be used as a marker for cells of some breast, colon, gastric, esophageal, pancreatic, duodenal, lung, bladder and renal carcinomas and gastric and islet cell neuroendocrine tumors. The invention also provides for numerous polynucleotide encoding humanized Lewis Y specific antibodies, expression vectors for producing humanized Lewis Y specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized Lewis Y specific antibodies. Additionally, the invention provides methods of treating cancer using humanized Lewis Y specific antibodies.
摘要翻译：本发明提供对抗原Lewis Y特异性的几种人源化鼠抗体的产生，其被鼠抗体Lewis Y识别。Lewis Y抗原在正常组织中表达，但在某些肿瘤类型中表达水平较高，因此抗原可用作乳腺癌，结肠癌，胃癌，食管癌，胰腺癌，十二指肠癌，肺癌，膀胱癌和肾癌和胃和胰岛细胞神经内分泌肿瘤的细胞标志物。本发明还提供编码人源化Lewis Y特异性抗体的许多多核苷酸，用于产生人源化Lewis Y特异性抗体的表达载体和用于重组产生人源化抗体的宿主细胞。本发明还提供使用人源化Lewis Y特异性抗体检测癌细胞（体外和体内）的方法。另外，本发明提供使用人源化Lewis Y特异性抗体治疗癌症的方法。

18. 发明授权

US5952484A Recombinant human anti-LK26 antibodies 失效
标题翻译：重组人抗LK26抗体
公开(公告)号：US5952484A
公开(公告)日：1999-09-14
申请号：US760840
申请日：1996-12-05
申请人： Thomas Paul Wallace , William Joseph Harris , Francis Joseph Carr , Wolfgang J. Rettig , Pilar Garin-Chesa , Lloyd J. Old
发明人： Thomas Paul Wallace , William Joseph Harris , Francis Joseph Carr , Wolfgang J. Rettig , Pilar Garin-Chesa , Lloyd J. Old
IPC分类号： G01N33/574 , G01N33/68 , C07H21/02
CPC分类号： G01N33/6854 , G01N33/57484 , G01N33/6833
摘要： The invention provides for the production of several humanized murine antibodies specific for the antigen LK26, which is recognized by the murine antibody LK26. This antigen is expressed on all choriocarcinoma, teratocarcinoma and renal cancer cell lines whereas it is not expressed on cell lines of leukaemias, lymphomas, neuroectodermally-derived and epithelial tumour cell lines (excepting a small subset of epithelial cell lines). Furthermore, whereas renal cancer cell lines express the LK26 antigen, normal renal epithelial cells do not. Similarly, with the exception of the trophoblast, all normal adult and fetal tissues tested are negative for the LK26 phenotype. The invention also provides for numerous polynucleotide encoding humanized LK26 specific antibodies, expression vectors for producing humanized LK26 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized LK26 specific antibodies. Additionally, the invention provides methods of treating cancer using LK26 specific antibodies.
摘要翻译：本发明提供了针对抗原LK26特异的几种人源化鼠抗体的产生，其被鼠抗体LK26识别。该抗原在所有绒毛膜癌，畸胎癌和肾癌细胞系中表达，而不在白血病，淋巴瘤，神经外胚层衍生的和上皮性肿瘤细胞系的细胞系（除了上皮细胞系的一小部分之外）上表达。此外，肾癌细胞株表达LK26抗原时，肾上皮细胞不正常。类似地，除了滋养层之外，所有正常的成年和胎儿组织都检测到LK26表型阴性。本发明还提供编码人源化LK26特异性抗体的许多多核苷酸，用于产生人源化LK26特异性抗体的表达载体和用于重组产生人源化抗体的宿主细胞。本发明还提供了使用人源化LK26特异性抗体检测癌细胞（体外和体内）的方法。另外，本发明提供使用LK26特异性抗体治疗癌症的方法。

19. 发明授权

US5874060A Recombinant human anti-Lewis Y antibodies 失效
公开(公告)号：US5874060A
公开(公告)日：1999-02-23
申请号：US859649
申请日：1997-05-20
申请人： Kathryn Lesley Armour , Francis Joseph Carr , Lloyd J. Old , Elisabeth Stockert , Sydney Welt , Kunio Kitamura , Pilar Garin-Chesa
发明人： Kathryn Lesley Armour , Francis Joseph Carr , Lloyd J. Old , Elisabeth Stockert , Sydney Welt , Kunio Kitamura , Pilar Garin-Chesa
IPC分类号： C07K16/30 , C07K16/34 , A61K51/00 , A61K39/395
CPC分类号： C07K16/34 , C07K16/30 , C07K2317/24 , C07K2319/00
摘要： The invention provides for the production of several humanized murine antibodies specific for the antigen Lewis Y, which is recognized by the murine antibody Lewis Y. The Lewis Y antigen is expressed in normal tissues but the level of expression is higher in certain tumor types so that the antigen can be used as a marker for cells of some breast, colon, gastric, esophageal, pancreatic, duodenal, lung, bladder and renal carcinomas and gastric and islet cell neuroendocrine tumors. The invention also provides for numerous polynucleotide encoding humanized Lewis Y specific antibodies, expression vectors for producing humanized Lewis Y specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized Lewis Y specific antibodies. Additionally, the invention provides methods of treating cancer using humanized Lewis Y specific antibodies.

20. 发明授权

US5811522A Recombinant humanized anti-FB5 antibodies 失效
标题翻译：重组人源化抗FB5抗体
公开(公告)号：US5811522A
公开(公告)日：1998-09-22
申请号：US657012
申请日：1996-05-20
申请人： Thomas Paul Wallace , Francis Carr , Wolfgang J. Rettig , Pilar Garin-Chesa , Lloyd J. Old
发明人： Thomas Paul Wallace , Francis Carr , Wolfgang J. Rettig , Pilar Garin-Chesa , Lloyd J. Old
IPC分类号： C07K16/30 , C12N15/13 , C07K16/46 , C07K14/00
CPC分类号： C07K16/30 , C07K2317/24 , C07K2319/00
摘要： The invention provides for the production of several humanized murine antibodies specific for the antigen FB5, which is recognized by the murine antibody FB5. The FB5 antigen is expressed on the luminal surface of vascular endothelial cells of a wide range of malignant tumours. The invention also provides for numerous polynucleotide encoding humanized FB5 specific antibodies, expression vectors for producing humanized FB5 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized FB5 specific antibodies. Additionally, the invention provides methods of treating cancer using FB5 specific antibodies.
摘要翻译：本发明提供了针对抗原FB5特异的几种人源化鼠抗体的产生，其被鼠抗体FB5识别。 FB5抗原在广泛恶性肿瘤的血管内皮细胞的腔表面上表达。本发明还提供编码人源化FB5特异性抗体的许多多核苷酸，用于产生人源化FB5特异性抗体的表达载体和用于重组产生人源化抗体的宿主细胞。本发明还提供使用人源化FB5特异性抗体检测癌细胞（体外和体内）的方法。另外，本发明提供了使用FB5特异性抗体治疗癌症的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式